The European Society of Endocrinology (ESE) and the European Society for Paediatric Endocrinology (ESPE) have released the EndoCompass Research Roadmap: Directions for the Future of Endocrine Science. The supplement is published today in the European Journal of Endocrinology and is a major new initiative to align research efforts, improve funding strategies and increase the visibility of hormone-related health challenges across Europe.  

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone. The finding is based on an analysis of the complete data from the phase 3 global FLAURA2 study, co-led by researchers from Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France).

Researchers at the Federal University of São Carlos used pieces of cork and lasers to create a mechanism that detects the presence of the substance, which has potential carcinogenic effects, in mineral water, orange juice, and wine.

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the main causes of cancer-related mortality. Precisely predicting whether this type of tumour will reappear remains one of the key challenges in oncology. To try and make progress in this field, an international team led by the Universitat Rovira i Virgili has developed an artificial intelligence model that brings together medical imaging data and clinical information to calculate the risk of tumour recurrence in a much more accurate and interpretative way.

Cancer cells are known to reawaken embryonic genes to grow. A new study reveals the disease also hijacks the proteins, or “editors”, that control how those genes are read. The findings help explain why tumours grow so fast and adapt so well, and may point the way to new treatments.

Mikkael Sekeres, M.D., M.S., chief of the Division of Hematology at Sylvester Comprehensive Cancer Center, has been elected to the Executive Committee of the American Society of Hematology (ASH), the world’s largest professional organization dedicated to conquering blood diseases.

In the hunt for new therapeutics for cancer and infectious diseases, lasso peptides prove to be a catch. Their knot-like structures afford these molecules high stability and diverse biological activities, making them a promising avenue for new therapeutics. To better unleash their clinical potential, a team from the Carl R. Woese Institute for Genomic Biology developed LassoESM, a new large language model for predicting lasso peptide properties.